References
- Callaghan TM, Wilhelm KP. A review of ageing and an examination of clinical methods in the assessment of ageing skin. Part I: Cellular and molecular perspectives of skin ageing. Int J Cosmet Sci. 2008;30:313–322.
- Lanzl I, Merté RL. Treatment of wrinkles with botulinum toxin. Ophthalmologe. 2007;104:777–782.
- Bowler PJ. Dermal and epidermal remodelling using botulinum toxin type A for facial, non reducible, hyperkinetic lines: two case studies. J Cosmet Dermatol. 2008;7:241–244.
- Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35:1–8.
- Mueller HS, Antman EM, Ferst JA, Muller JE. Nifedipine in the treatment of cardiovascular disease. Pharmacotherapy. 1981;1:78–94.
- Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs. 2008;68:283–297.
- Andre P. New trends in face rejuvenation by hyaluronic acid injections. J Cosmet Dermatol. 2008;7:251–258.
- Morris CL, Stinnett SS, Woodward JA. Patient-preferred sites of restylane injection in periocular and facial soft-tissue augmentation. Ophthalmol Plast Reconstr Surg. 2008;24:117–121.
- Stewart DB, Morganroth GS, Mooney MA, Cohen J, Levin PS, Gladstone HB. Management of visible granulomas following periorbital injection of poly-L-lactic acid. Ophthalmol Plast Reconstr Surg. 2007;23:298–301.
- Apikian M, Roberts S, Goodman GJ. Adverse reactions to polylactic acid injections in the periorbital area. J Cosmet Dermatol. 2007;6:95–101.